5Wang J, Wiley JM, Luddy R, et al. Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. J Pediatr,2005,146(2):217 221.
6Bennett CM,Rogers ZR,Kinnamon DD,et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood, 2006, 107(7): 2639-2642.
7Penalver FJ ,Jimenez-Yuste V, Almagro M ,et al. On behalf of the Multi-institutional Retrospective Spanish Study on the use of rituximab in refractory ITP. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. Ann Hematol, 200685 (6) : 400-406.
8Cesaro S,Bisogno G,Pusiol A. Rituximab and factors predictive of response in chronic immune thrombocytopenic purpura of children. J Pediatr,2005,147(5):715-716.
9British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults,children and in pregnancy. Br J Haematol, 2003, 120(4) :574-596.
10McFarland J. Pathophysiology of platelet destruction in immune(idiopathic) thrombocytopenic purpura. Blood Rev, 2002,16 ( 1 ) : 1-2.
10Buskard N, Rock G, Nair R. The Canadian experience using plasma exchange fir immune thrombocytopenic purpura. Canadian Apheresis Group [J]. Transfus Sci, 1998,19 ( 3 ) :295 - 300.
